Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections. (February 2015)

• Record Type: Journal Article
• Authors: Bassetti, Matteo; Righi, Elda
• Is Part Of: Future microbiology. Volume 10:Number 2(2015:Feb.)
• Page Start: 151
• Page End: 160
• Publication Date: 2015-02
• Subjects: ceftolozane/tazobactam -- cephalosporins -- Pseudomonas aeruginosa -- resistant Gram-negative bacteria; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb.14.112
• Languages: English
• ISSNs: 1746-0913

Abstract

ABSTRACT : High rates of morbidity and mortality have been linked to the emergence of antimicrobial-resistant Gram-negative pathogens, especially in the hospital setting. Infections due to extended-spectrum-β-lactamase producing Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae ) and multidrug-resistant Pseudomonas aeruginosa pose a major health threat and dramatically reduce the therapeutic options to achieve an appropriate treatment. There is a need for novel antimicrobials that could provide clinical efficacy toward multidrug-resistant Gram-negative pathogens, including extended-spectrum-β-lactamase and carbapenemase producers. Ceftolozane/tazobactam is a novel antipseudomonal cephalosporin associated with a well-established β-lactamase inhibitor currently in clinical development for the treatment of complicated intra-abdominal infections, complicated urinary tract infections and nosocomial pneumonia. Phase II and III trials have shown high efficacy and good tolerability in complicated urinary and intra-abdominal infections compared with standard therapy. A study for the treatment of nosocomial pneumonia is planned.